CN111533662B - Synthesis method of citalopram intermediate - Google Patents
Synthesis method of citalopram intermediate Download PDFInfo
- Publication number
- CN111533662B CN111533662B CN202010263399.8A CN202010263399A CN111533662B CN 111533662 B CN111533662 B CN 111533662B CN 202010263399 A CN202010263399 A CN 202010263399A CN 111533662 B CN111533662 B CN 111533662B
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- sodium borohydride
- under
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/02—Formation of carboxyl groups in compounds containing amino groups, e.g. by oxidation of amino alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/14—Preparation of carboxylic acid nitriles by reaction of cyanides with halogen-containing compounds with replacement of halogen atoms by cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
- C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
- C07C29/147—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of carboxylic acids or derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention provides a preparation method of citalopram intermediate 4- (4- (dimethylamino) -1- (4-fluorophenyl) -1-hydroxybutyl) -3- (hydroxymethyl) benzonitrile. The method has the advantages of cheap and easily obtained raw materials, short reaction steps, high yield, simple post-treatment, easy operation and the like, reduces the cost, has certain technical advantages, and is suitable for large-scale industrial production.
Description
Technical Field
The invention relates to the field of synthesis of pharmaceutical intermediates, in particular to a preparation method of a citalopram intermediate 4- (4- (dimethylamino) -1- (4-fluorophenyl) -1-hydroxybutyl) -3- (hydroxymethyl) benzonitrile. The information provided is intended only to aid the reader in understanding. Neither the information provided nor the references cited are admissions of prior art for the invention. Each reference cited is incorporated herein in its entirety and can be used for any purpose.
Background
Citalopram (Citalopram) was developed by LUNDBECK, denmark as a selective 5-hydroxytryptamine reuptake inhibitor (SSRI) that selectively inhibits the 5-HT transporter, blocks the reuptake of 5-HT by the presynaptic membrane, prolongs and increases the effects of 5-HT, and thus produces antidepressant effects.
4- (4- (dimethylamino) -1- (4-fluorophenyl) -1-hydroxybutyl) -3- (hydroxymethyl) benzonitrile is an important intermediate for preparing citalopram bulk drug, and the synthetic route thereof is reported at home and abroad, and is summarized as follows:
bogeso et al (US4650884) use 5-cyanophthalide as starting material, and perform Grignard reaction with p-fluorophenyl magnesium bromide and 3, 3-dimethylaminopropyl magnesium chloride twice, and then hydrolyze to obtain 4- (4- (dimethylamino) -1- (4-fluorophenyl) -1-hydroxybutyl) -3- (hydroxymethyl) benzonitrile according to the following synthetic route:
the method has short route, but the starting raw materials are expensive and not easy to obtain, and the synthesis pollution is large. In addition, the reaction needs twice lattice reagents, and the reaction is harsh; in addition, the used format reagent is not a common reagent and is expensive; and secondly, the reaction selectivity is poor, the yield is low, and the finishing cost is high.
Similar methods have been reported in other documents and patents, and the main purpose is to solve the problem of 5-cyanophthalide as a starting material, and the main difference is that the substituent at the 5-position is different, and the cyano group is constructed by coupling or amide dehydration or the like at the later stage.
The document (J.Am.chem.Soc.2016,138,3294-3297) reports a novel process for the synthesis of 4- (4- (dimethylamino) -1- (4-fluorophenyl) -1-hydroxybutyl) -3- (hydroxymethyl) benzonitrile by the following route:
the method comprises the steps of constructing a cyano group by oxidizing m-xylene which is cheap and is used as a starting material, converting methyl into hydroxymethyl through 3 steps of reaction, and reacting with ketone under the action of tert-butyl lithium to generate a target intermediate. The intermediate uses a class of solvents of carbon tetrachloride and heavy metal of silver nitrate, and the final step uses extremely dangerous tert-butyl lithium, and the yield is low, and the intermediate is purified by column chromatography, so the total cost is high, and the industrial production is not facilitated.
Aiming at the defects of the process route, the invention provides a synthetic route of a citalopram intermediate 4- (4- (dimethylamino) -1- (4-fluorophenyl) -1-hydroxybutyl) -3- (hydroxymethyl) benzonitrile and a preparation method thereof. The method has the advantages of short route, easily obtained raw materials, low cost, simple and convenient operation, convenient separation and purification in each step, high yield and good product quality, and can be used for large-scale industrial preparation of citalopram intermediate and raw material medicines.
Disclosure of Invention
The application provides a synthetic route of a citalopram intermediate 4- (4- (dimethylamino) -1- (4-fluorophenyl) -1-hydroxybutyl) -3- (hydroxymethyl) benzonitrile and a preparation method thereof, and the compound can be applied to preparation of citalopram bulk drugs.
The invention provides a method for preparing a citalopram intermediate VI, which comprises the following steps:
wherein, in the process of the step (1), the compound of the formula I and dimethylamine or hydrochloride thereof react at 0-150 ℃ under the condition of solvent or no solvent to prepare a compound of the formula II;
wherein in the process of the step (2), the compound of the formula III reacts with the compound of the formula II under the action of a metal reagent in an aprotic organic solvent at a temperature of between 78 ℃ below zero and 30 ℃ under the protection of inert gas to prepare a compound of the formula IV;
wherein in the process of the step (3), the compound of the formula IV reacts with a reducing agent in an organic solvent at the temperature of-20-100 ℃ to prepare a compound of the formula V;
wherein, in the process of the step (4), under the protection of inert gas at 50-200 ℃, the compound of the formula V and metal cyanide react in a solvent under the action of an organic phosphine ligand and a transition metal catalyst to prepare the compound of the formula VI.
In some embodiments, during step (1), a compound of formula I and dimethylamine, or its hydrochloride salt, are reacted at 60 ℃ to 100 ℃ in the presence or absence of a solvent to produce a compound of formula II, wherein the solvent is selected from one or more of water, methanol, ethanol, isopropanol, tetrahydrofuran, methyl tert-butyl ether, 2-methyltetrahydrofuran, acetonitrile, acetone, N-dimethylformamide, N-diethylacetamide, N-methylpyrrolidone, or dimethylsulfoxide; the equivalent of dimethylamine or hydrochloride thereof is 1.0-5.0 equivalents.
In some embodiments, during step (1), under the action of a base, the compound of formula I and dimethylamine or the hydrochloride thereof react at 0 ℃ to 150 ℃ under the action of a solvent or no solvent to prepare the compound of formula II, wherein the base is selected from potassium carbonate, sodium bicarbonate, triethylamine, diisopropylethylamine or pyridine, and the using equivalent of the base is 1.0 to 5.0.
In some embodiments, during step (2), the compound of formula IV is prepared by reacting a compound of formula III with a compound of formula II in an aprotic organic solvent under the influence of a metal reagent at-78 ℃ to 0 ℃ under nitrogen atmosphere, wherein the aprotic organic solvent is selected from tetrahydrofuran or dimethyltetrahydrofuran; the metal reagent is selected from n-butyl lithium, isopropyl magnesium bromide or isopropyl magnesium chloride.
In some embodiments, the compound of formula IV is reacted with a reducing agent in tetrahydrofuran at-20 ℃ to 80 ℃ during step (3) to produce the compound of formula V; preferably, the reducing agent is selected from borane dimethylsulfide complex, borane tetrahydrofuran complex, lithium aluminum hydride, sodium borohydride/I 2 Sodium borohydride/boron trifluoride etherate, sodium borohydride/zinc chloride, sodium borohydride/trifluoroacetic acid or sodium borohydride/sulfuric acid; more preferably, the reducing agent is selected from sodium borohydride/boron trifluoride etherate, sodium borohydride/zinc chloride or sodium borohydride/sulfuric acid.
In some embodiments, the compound of formula V is reacted with a metal cyanide under the action of an organophosphine ligand and a transition metal catalyst in a solvent at 70 ℃ to 150 ℃ under nitrogen protection during step (4) to produce the compound of formula VI, wherein the compound of formula V is reacted with the metal cyanide under the action of the organophosphine ligand and the transition metal catalyst in a solvent at 50 ℃ to 200 ℃ under inert gas protection during step (4) to produce the compound of formula VI.
In some embodiments, during step (4), the compound of formula V is reacted with a metal cyanide under the action of an organophosphine ligand and a transition metal catalyst in a solvent at 50 ℃ to 200 ℃ under inert gas to produce the compound of formula VI, wherein the metal cyanide is zinc cyanide or cuprous cyanide.
In other embodiments, during step (4), reacting a compound of formula V with a metal cyanide in a solvent under an inert gas atmosphere at 50 ℃ to 200 ℃ under the action of an organophosphine ligand and a transition metal catalyst to produce a compound of formula VI, wherein the organophosphine ligand is selected from 1,1' -bis (diphenylphosphino) ferrocene, 2-dicyclohexylphosphine-2, 4, 6-triisopropylbiphenyl, or triphenylphosphine; the transition metal catalyst is selected from bis (triphenylphosphine) nickel chloride, tetratriphenylphosphine palladium, tris (dibenzylideneacetone) dipalladium, [1,1 '-bis (diphenylphosphino) ferrocene ] palladium dichloride and [1,1' -bis (diphenylphosphino) ferrocene ] palladium dichloride dichloromethane complex.
The present invention also provides another process for the preparation of a citalopram intermediate, said process comprising the steps of:
wherein in the process of the step (1), the compound shown in the formula III reacts with sodium borohydride/boron trifluoride ethyl ether, sodium borohydride/zinc chloride or sodium borohydride/sulfuric acid in tetrahydrofuran at the temperature of-20-80 ℃ to prepare a compound shown in the formula VII;
wherein in the process of the step (2), under the protection of nitrogen gas at-78-0 ℃, a compound of formula VII in tetrahydrofuran or 2-methyltetrahydrofuran reacts with a compound of formula II under the action of n-butyl lithium, isopropyl magnesium bromide or isopropyl magnesium chloride to prepare a compound of formula V;
in the process of the step (3), under the protection of nitrogen and at 70-150 ℃, reacting a compound shown in a formula V with metal cyanide in a solvent under the action of an organic phosphine ligand and a transition metal catalyst to prepare a compound shown in a formula VI, wherein the solvent is selected from one or more of water, ethanol, isopropanol, acetonitrile, dioxane, ethylene glycol dimethyl ether, toluene, dimethyl sulfoxide, N-dimethylformamide, N-dimethylacetamide and N-methylpyrrolidone; the metal cyanide is zinc cyanide or cuprous cyanide; the organophosphorus ligand is selected from 1,1' -bis (diphenylphosphino) ferrocene, 2-dicyclohexyl phosphorus-2, 4, 6-triisopropyl biphenyl or triphenylphosphine; the transition metal catalyst is selected from bis (triphenylphosphine) nickel chloride, tetratriphenylphosphine palladium, tris (dibenzylideneacetone) dipalladium, [1,1 '-bis (diphenylphosphino) ferrocene ] palladium dichloride and [1,1' -bis (diphenylphosphino) ferrocene ] palladium dichloride dichloromethane complex.
By means of the scheme, compared with the prior art, the invention has the following advantages: the invention provides a preparation method of a citalopram intermediate 4- (4- (dimethylamino) -1- (4-fluorophenyl) -1-hydroxybutyl) -3- (hydroxymethyl) benzonitrile, which can be used as a raw material drug of citalopram. The method has the advantages of short synthetic route, cheap and easily-obtained raw materials, simple overall process and strong operability, and is suitable for industrial production.
Detailed Description
The preparation described in the present invention is further illustrated by the following examples, which include, but are not limited to.
The following examples are intended only to illustrate specific embodiments of the present invention, so as to enable those skilled in the art to more fully understand the present invention, but not to limit the present invention in any way. In the embodiments of the present invention, technical means or methods which are not specifically described are conventional in the art.
The chemicals used in the following examples are all commercially available chemicals.
In an exemplary embodiment of the invention, the synthetic route for formula VI is as follows:
(1) route one
(2) Route two
In the above synthetic routes, those skilled in the art can also make changes to the above synthetic routes, such as changing specific reaction conditions or making adjustments to the synthetic route of one or more steps, etc., as needed, and such changes are within the scope of the present application without departing from the spirit of the present invention.
EXAMPLE 14 Synthesis of- (dimethylamino) -1- (4-fluorophenyl) butan-1-one hydrochloride
To a 250mL three-necked flask were added 4-chloro-1- (4-fluorophenyl) butan-1-one (20.1g,0.1mmol), dimethylamine (40% in water, 20mL) and ethanol (100mL) in that order. The reaction was refluxed for 16h, cooled to room temperature, concentrated under reduced pressure, then added with water and extracted with ethyl acetate. The organic phase is washed once more with water, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was dissolved in acetone, hydrogen chloride gas was introduced, stirred for 1h and filtered under suction to give the hydrochloride of formula II (21.3g, 86.9%).
EXAMPLE 24 Synthesis of (dimethylamino) -1- (4-fluorophenyl) butan-1-one
To a 250mL three-necked flask were added 4-chloro-1- (4-fluorophenyl) butan-1-one (20.1g,0.1mmol), dimethylamine hydrochloride (16.3g,0.2mol), potassium carbonate (27.6g,0.2mol), and DMF (100mL) in that order. Reacting at 80 ℃ for 16h, cooling to room temperature, adding saturated saline, and extracting with ethyl acetate. The organic phase is washed once more with saturated salt water, dried with anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. Dissolving the crude product in acetone, introducing hydrogen chloride gas, stirring for 1h, and performing suction filtration to obtain the hydrochloride of the formula II. The hydrochloride salt of formula II was dissolved in water, extracted with aqueous sodium bicarbonate until no gas was formed, EA extracted, dried and concentrated until use (20.5g, 83.4%).
EXAMPLE 35 Synthesis of chloro-2- (4- (dimethylamino) -1- (4-fluorophenyl) -1-hydroxybutyl) benzoic acid
N-butyllithium (2.5M/hexane, 0.11mol,44.0mL) was carefully added dropwise to 5-chloro-2-bromobenzoic acid (11.8g,0.05mol) in anhydrous THF (100mL) at-78 ℃ under nitrogen. After 1h of incubation, a solution of 4- (dimethylamino) -1- (4-fluorophenyl) butan-1-one (10.5g,0.05mol) in THF (20mL) was added dropwise. After the addition was completed, the reaction was allowed to warm to-60 ℃ for 2 hours, and then quenched by the addition of saturated ammonium chloride (100 mL). The mixture was extracted with ethyl acetate, washed with saturated ammonium chloride and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was slurried with dichloromethane to give a white solid (15.3g, 83.5%).
EXAMPLE 45 Synthesis of chloro-2- (4- (dimethylamino) -1- (4-fluorophenyl) -1-hydroxybutyl) benzoic acid
To 5-chloro-2-bromobenzoic acid (11.8g,0.05mol) in anhydrous 2-methyltetrahydrofuran (100mL) was carefully added isopropyl magnesium bromide (2.9M/2-methyltetrahydrofuran, 0.11mol,37.9mL) dropwise at-78 ℃ under nitrogen. After 1h of incubation, a solution of 4- (dimethylamino) -1- (4-fluorophenyl) butan-1-one (10.5g,0.05mol) in 2-methyltetrahydrofuran (20mL) was added dropwise. After the addition was completed, the reaction was allowed to warm to-40 ℃ for 2 hours, and then quenched by the addition of saturated ammonium chloride (100 mL). The mixture was extracted with ethyl acetate, washed with saturated ammonium chloride and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was slurried with dichloromethane to give a white solid (14.8g, 80.9%).
EXAMPLE 51 Synthesis of- (4-chloro-2- (hydroxymethyl) phenyl) -4- (dimethylamino) -1- (4-fluorophenyl) butan-1-ol
Add sodium borohydride (1.24g,32.8mmol) portionwise to a solution of 5-chloro-2- (4- (dimethylamino) -1- (4-fluorophenyl) -1-hydroxybutyl) benzoic acid (10.00g,27.3mmol) in THF (60 mL). The temperature is reduced to 0 ℃, then boron trifluoride ethyl ether solution (5.3mL,32.8mmol) is added dropwise, and the solution is added within 1 h. The reaction solution was warmed to 25 ℃ and stirred for 16 h. Cooled to 0 ℃, aqueous sodium hydroxide (1N,44mL) was carefully added dropwise and stirred for 3 h. Then extracted with ethyl acetate, washed once with water, dried and concentrated. The product was used in the next reaction without further purification.
EXAMPLE 64 Synthesis of (4- (dimethylamino) -1- (4-fluorophenyl) -1-hydroxybutyl) -3- (hydroxymethyl) benzonitrile
1- (4-chloro-2- (hydroxymethyl) phenyl) -4- (dimethylamino) -1- (4-fluorophenyl) butan-1-ol (9.6g,27.3mmol), zinc cyanide (9.6g,81.9mmol) and 1,1' -bis (diphenylphosphino) ferrocene (1.5g,2.7mmol) were placed in a dry three-necked flask, nitrogen was purged three times and anhydrous DMF (50mL) was added. Pd (dppf) C1 was added under a stream of nitrogen 2 ·CH 2 Cl 2 (1.1g,1.4 mmol). Then the reaction bottle is placed in an oil bath at 130 ℃ for reaction for 36 hours, then the reaction bottle is moved to room temperature for cooling, and water is added for quenching reaction. The mixture was filtered through celite and extracted with ethyl acetate. The combined organic phases were washed twice with saturated brine, dried over anhydrous sodium sulfate, concentrated and the crude product slurried with n-heptane/ethyl acetate to give a pale yellow solid (7.7g, 82% yield over two steps).
EXAMPLE synthesis of 74- (4- (dimethylamino) -1- (4-fluorophenyl) -1-hydroxybutyl) -3- (hydroxymethyl) benzonitrile
1- (4-chloro-2- (hydroxymethyl) phenyl) -4- (dimethylamino) -1- (4-fluorophenyl) butan-1-ol (3.5g,10.0mmol), zinc cyanide (3.5g,30.0mmol) and triphenylphosphine (526mg,2.0mmol) were placed in a dry three-necked flask and nitrogen was purged three times and anhydrous DMF (20mL) was added. Tetratriphenylphosphine palladium (1.2g,1.0mmol) was added under a nitrogen stream. Then the reaction bottle is placed in an oil bath at 150 ℃ for reaction for 36 hours, then the reaction bottle is moved to room temperature for cooling, and water is added for quenching reaction. The mixture was filtered through celite and extracted with ethyl acetate. The organic phases were combined and washed twice with saturated brine, dried over anhydrous sodium sulfate, concentrated and purified by crude column chromatography to give a pale yellow solid (1.6g, 47%).
EXAMPLE 8 Synthesis of (2-bromo-5-chlorophenyl) methanol
To a solution of 5-chloro-2-bromobenzoic acid (23.5g,0.10mol) in THF (100mL) was added sodium borohydride (4.6g,0.12mol) in portions. The temperature is reduced to 0 ℃, then boron trifluoride ethyl ether solution (19.4mL,0.12mol) is added dropwise, and the dropwise addition is finished within 1 h. The reaction solution was warmed to 25 ℃ and stirred for 16 h. Cooled to 0 ℃, aqueous sodium hydroxide (1N,160mL) was carefully added dropwise and stirred for 3 h. Then extracted with ethyl acetate, washed once with water, dried and concentrated. The product was used directly in the next reaction without further purification.
Example Synthesis of 91- (4-chloro-2- (hydroxymethyl) phenyl) -4- (dimethylamino) -1- (4-fluorophenyl) butan-1-ol
To (2-bromo-5-chlorophenyl) methanol (22.1g,0.10mol) in dry THF (150mL) at-78 deg.C under nitrogen was added n-butyllithium (2.5M/hexane, 0.22mol,88.0mL) carefully dropwise. The incubation was completed for 1h and then a solution of 4- (dimethylamino) -1- (4-fluorophenyl) butan-1-one (20.9g,0.10mol) in THF (50mL) was added dropwise. After the addition was completed, the reaction was allowed to warm to-60 ℃ for 2 hours, and then quenched by the addition of saturated ammonium chloride (100 mL). Most of the organic solvent was concentrated, and the mixture was extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was slurried with n-heptane/ethyl acetate to give a pale yellow solid (29.9g, 85.0%).
The above-mentioned embodiments are merely exemplary embodiments for fully illustrating the present invention, and the scope of the present invention is not limited to the above-mentioned embodiments, but defined by the contents of the claims. All matter disclosed in the specification, including the abstract, and all methods and steps disclosed, may be combined in any combination, except combinations where features and/or steps are mutually exclusive. Each feature disclosed in this specification, including the abstract, can be replaced by alternative features serving the same, equivalent or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each feature disclosed is one example only of a generic series of equivalent or similar features. Those skilled in the art should also realize that such equivalent substitutions and alterations can be made without departing from the spirit and scope of the present invention. Such modifications are also intended to be within the scope of the present invention. Each reference cited in this application is incorporated herein in its entirety.
Claims (8)
1. A process for the preparation of a citalopram intermediate characterized in that: the method comprises the following steps:
in the process of the step (1), under the condition of solvent or no solvent, the compound shown in the formula I and dimethylamine or hydrochloride thereof react at the reaction temperature of 0-150 ℃ to prepare a compound shown in the formula II;
in the process of the step (2), under the protection of a reaction temperature of-78-30 ℃ and inert gas, a compound of a formula III reacts with a compound of a formula II in an aprotic organic solvent under the action of a metal reagent to prepare a compound of a formula IV; wherein the metal reagent is selected from n-butyl lithium, isopropyl magnesium bromide or isopropyl magnesium chloride;
wherein in the process of the step (3), the compound shown in the formula IV reacts with a reducing reagent in an organic solvent at a reaction temperature of-20-100 ℃ to prepare a compound shown in the formula V; wherein the reducing agent is selected from borane dimethyl sulfide complexBorane tetrahydrofuran complex, lithium aluminum hydride, sodium borohydride/I 2 Sodium borohydride/boron trifluoride etherate, sodium borohydride/zinc chloride, sodium borohydride/trifluoroacetic acid or sodium borohydride/sulfuric acid;
in the process of the step (4), under the protection of inert gas and at the reaction temperature of 50-200 ℃, the compound of the formula V and metal cyanide react in a solvent under the action of an organic phosphine ligand and a transition metal catalyst to prepare the compound of the formula VI; wherein the metal cyanide is zinc cyanide or cuprous cyanide; wherein the organic phosphine ligand is selected from 1,1' -bis (diphenylphosphino) ferrocene, 2-dicyclohexyl phosphorus-2, 4, 6-triisopropyl biphenyl or triphenylphosphine; the transition metal catalyst is selected from a bis (triphenylphosphine) nickel chloride, tetratriphenylphosphine palladium, tris (dibenzylideneacetone) dipalladium, [1,1 '-bis (diphenylphosphino) ferrocene ] palladium dichloride and a [1,1' -bis (diphenylphosphino) ferrocene ] palladium dichloride dichloromethane complex.
2. The process of claim 1, wherein the solvent in step (1) is selected from one or more of water, methanol, ethanol, isopropanol, tetrahydrofuran, methyl tert-butyl ether, 2-methyltetrahydrofuran, acetonitrile, acetone, N-dimethylformamide, N-diethylacetamide, N-methylpyrrolidone, or dimethylsulfoxide; the equivalent weight of the dimethylamine or the hydrochloride thereof is 1.0-5.0 equivalent weight; the reaction temperature is 60-100 ℃.
3. The method of claim 1, wherein the compound of formula I in step (1) is reacted with dimethylamine or hydrochloride thereof under the action of a base to prepare a compound of formula II, wherein the base is selected from potassium carbonate, sodium bicarbonate, triethylamine, diisopropylethylamine or pyridine, and the using equivalent of the base is 1.0-5.0.
4. The method of claim 1, wherein the inert gas in step (2) is nitrogen; the aprotic organic solvent is selected from tetrahydrofuran or dimethyltetrahydrofuran; the reaction temperature is-78 ℃ to 0 ℃.
5. The process of claim 1, wherein the organic solvent in step (3) is selected from the group consisting of tetrahydrofuran; the reaction temperature is-20 ℃ to 80 ℃.
6. The process of claim 1, wherein the reducing agent in step (3) is selected from sodium borohydride/boron trifluoride etherate, sodium borohydride/zinc chloride or sodium borohydride/sulfuric acid.
7. The process of claim 1, wherein the reaction temperature in step (4) is from 70 ℃ to 150 ℃; the inert gas is nitrogen; the solvent is selected from one or more of water, ethanol, isopropanol, acetonitrile, dioxane, ethylene glycol dimethyl ether, toluene, dimethyl sulfoxide, N-dimethylformamide, N-dimethylacetamide and N-methylpyrrolidone.
8. A process for the preparation of a citalopram intermediate characterized in that: the method comprises the following steps:
wherein in the process of the step (1), the compound shown in the formula III reacts with sodium borohydride/boron trifluoride ethyl ether, sodium borohydride/zinc chloride or sodium borohydride/sulfuric acid in tetrahydrofuran at the temperature of-20-80 ℃ to prepare a compound shown in the formula VII;
wherein in the process of the step (2), under the protection of nitrogen gas at-78-0 ℃, a compound of formula VII in tetrahydrofuran or 2-methyltetrahydrofuran reacts with a compound of formula II under the action of n-butyl lithium, isopropyl magnesium bromide or isopropyl magnesium chloride to prepare a compound of formula V;
in the process of the step (3), under the protection of nitrogen and at 70-150 ℃, reacting a compound shown in a formula V with metal cyanide in a solvent under the action of an organic phosphine ligand and a transition metal catalyst to prepare a compound shown in a formula VI, wherein the solvent is selected from one or more of water, ethanol, isopropanol, acetonitrile, dioxane, ethylene glycol dimethyl ether, toluene, dimethyl sulfoxide, N-dimethylformamide, N-dimethylacetamide and N-methylpyrrolidone; the metal cyanide is zinc cyanide or cuprous cyanide; the organophosphorus ligand is selected from 1,1' -bis (diphenylphosphino) ferrocene, 2-dicyclohexyl phosphorus-2, 4, 6-triisopropyl biphenyl or triphenylphosphine; the transition metal catalyst is selected from bis (triphenylphosphine) nickel chloride, tetratriphenylphosphine palladium, tris (dibenzylideneacetone) dipalladium, [1,1 '-bis (diphenylphosphino) ferrocene ] palladium dichloride and [1,1' -bis (diphenylphosphino) ferrocene ] palladium dichloride dichloromethane complex.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010263399.8A CN111533662B (en) | 2020-04-07 | 2020-04-07 | Synthesis method of citalopram intermediate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010263399.8A CN111533662B (en) | 2020-04-07 | 2020-04-07 | Synthesis method of citalopram intermediate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111533662A CN111533662A (en) | 2020-08-14 |
| CN111533662B true CN111533662B (en) | 2022-08-23 |
Family
ID=71976913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010263399.8A Active CN111533662B (en) | 2020-04-07 | 2020-04-07 | Synthesis method of citalopram intermediate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111533662B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114763329A (en) * | 2021-01-14 | 2022-07-19 | 浙江华海药业股份有限公司 | Method for purifying citalopram key intermediate |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001002383A2 (en) * | 1999-07-06 | 2001-01-11 | Lundbeck Pharmaceuticals Italy S.P.A. | Process for the synthesis of citalopram |
| CN1359382A (en) * | 1999-04-14 | 2002-07-17 | H·隆德贝克有限公司 | Method for preparing citalopram |
| CN1688565A (en) * | 2002-01-25 | 2005-10-26 | 埃斯特维化学股份有限公司 | Method of obtaining citalopram |
| CN104072390A (en) * | 2014-03-11 | 2014-10-01 | 江苏奥赛康药业股份有限公司 | Escitalopram compound and preparation method thereof |
| JP2019119710A (en) * | 2018-01-05 | 2019-07-22 | 株式会社トクヤマ | Process for producing hydrobromide of diol compound |
-
2020
- 2020-04-07 CN CN202010263399.8A patent/CN111533662B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1359382A (en) * | 1999-04-14 | 2002-07-17 | H·隆德贝克有限公司 | Method for preparing citalopram |
| WO2001002383A2 (en) * | 1999-07-06 | 2001-01-11 | Lundbeck Pharmaceuticals Italy S.P.A. | Process for the synthesis of citalopram |
| CN1688565A (en) * | 2002-01-25 | 2005-10-26 | 埃斯特维化学股份有限公司 | Method of obtaining citalopram |
| CN104072390A (en) * | 2014-03-11 | 2014-10-01 | 江苏奥赛康药业股份有限公司 | Escitalopram compound and preparation method thereof |
| JP2019119710A (en) * | 2018-01-05 | 2019-07-22 | 株式会社トクヤマ | Process for producing hydrobromide of diol compound |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111533662A (en) | 2020-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103562194A (en) | Method for synthesizing ketobenzofuran derivatives | |
| WO2021169359A1 (en) | Benzodihydrofuro heterocyclic compound and preparation method therefor | |
| CN112675919B (en) | Application of N-heterocyclic carbene-based mixed nickel (II) complex in synthesis of alpha-benzyl benzofuran compound | |
| US9238636B2 (en) | Process for preparation of dronedarone by Grignard reaction | |
| CN111533662B (en) | Synthesis method of citalopram intermediate | |
| WO2006124283A1 (en) | Bis-amination of aryl halides | |
| CN106831441A (en) | A kind of preparation method of cinacalcet hydrochloride | |
| CN111732516B (en) | A kind ofNProcess for preparing (E) -aryl-substituted heterocyclic compounds | |
| CN108276356B (en) | Preparation method of 3, 5-disubstituted thiazolidine-2-thioketone compound | |
| CN106795080B (en) | Process for the preparation of halogenated trifluoroacetophenones | |
| Meng et al. | Et 3 N-promoted tandem ring-opening reaction of N-tosylaziridines with terminal alkynoates: a straightforward synthesis of functionalized enamines | |
| CN111303096B (en) | Synthesis method of polysubstituted 1, 3-dihydronaphtho [2,3-c ] furan derivative | |
| CN107501159B (en) | Synthesis method of vilazodone intermediate 3- (4-chlorobutyl) -5-cyanoindole | |
| CN102964334B (en) | Process for synthesizing 2-thiopheneethanol and derivatives thereof | |
| CN102153483A (en) | Axial chirality vicinal diamine compound and preparation method thereof | |
| JP2017002002A (en) | Fluorine-containing organic compound and manufacturing method of biaryl compound by the same and grignard reagent | |
| CN115232094B (en) | Synthesis method of coumarin compound Murraol | |
| CN114832862B (en) | Catalytic composition for coupling reaction and application of catalytic composition in preparation of isoquinoline-1, 3-dione compounds | |
| CN110372718B (en) | Difluoromethane thiochromanonthiophene compound and preparation method thereof | |
| CN103145664A (en) | Method of preparing vilazodone intermediate 5-piperazin-2-acyl substituted benzofuran | |
| CN113354582B (en) | Method for catalytically synthesizing 1, 2-dihydroisoquinoline compounds by utilizing iridium complexes | |
| CN111423405B (en) | Method for synthesizing benzopyran 3 alcohol derivative compound | |
| CN108358793B (en) | Secondary amine compound synthesized from alkyne and synthesis method thereof | |
| CN107501061A (en) | A kind of preparation method of the ketone of 2 methoxyl group, 6,7,8,9 tetrahydro benzo cycloheptane 5 | |
| JP4509327B2 (en) | Process for producing N, N-disubstituted-4-aminocrotonic acid ester |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: The third and fourth floors of Block B, No. 177 Jinda Road, Jianxin Town, Cangshan District, Fuzhou City, Fujian Province, 350000 Patentee after: Fujian Haixi New Pharmaceutical Co.,Ltd. Address before: No.1 building, No.20 Jinzhou North Road, Jianxin Town, Cangshan District, Fuzhou City, Fujian Province 350028 Patentee before: FUJIAN HAIXI PHARMACEUTICALS Co.,Ltd. |
|
| CP03 | Change of name, title or address |